Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | PGD | P52209 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29431969 | 1.00 | LMNA (0.42) | LMNAL3MBTL1PTPN1TDP1PDE4A | |
| SCHEMBL27468464 | 0.94 | LMNA (0.46) | LMNAL3MBTL1PTPN1TDP1PDE4A | |
| SCHEMBL29886751 | 0.94 | LMNA (0.46) | LMNAL3MBTL1PTPN1TDP1PDE4A | |
| SCHEMBL8854308 | 0.89 | PTPN1 (0.41) | PTPN1TDP1MPIPGDSMPD1 | |
| SCHEMBL28033517 | 0.86 | PTPN1 (0.43) | LMNAL3MBTL1PTPN1TDP1MPI | |
| SCHEMBL2216482 | 0.86 | PTPN1 (0.43) | LMNAL3MBTL1PTPN1TDP1MPI | |
| SCHEMBL1921547 | 0.83 | PTPN1 (0.36) | LMNAL3MBTL1PTPN1TDP1PDE4A | |
| SCHEMBL3507130 | 0.83 | PTPN1 (0.36) | LMNAL3MBTL1PTPN1TDP1PDE4A | |
| SCHEMBL3507128 | 0.83 | PTPN1 (0.36) | LMNAL3MBTL1PTPN1TDP1PDE4A | |
| SCHEMBL5789757 | 0.83 | PTPN1 (0.36) | LMNAL3MBTL1PTPN1TDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130930-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS | NAT JEWISH HEALTH (US) | 2026-05-14 | — | — | US | disclosed |
| US-12472193-B2 | Methods and compositions for treating and preventing respiratory related diseases and conditions with xylitol-headgroup lipid analogs | NATIONAL JEWISH HEALTH (US) | 2025-11-18 | — | — | US | disclosed |
| US-20240277737-A1 | METHOD FOR GENERATING DRY POWDER SUITABLE FOR INHALATION ADMINISTRATION OF ANTIMICROBIAL PHOSPHOLIPID COMPOSITIONS | CELESTIAL THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2023028354-A1 | METHOD FOR GENERATING DRY POWDER SUITABLE FOR INHALATION/INTRANASAL/INTRATRACHEAL ADMINISTRATION OF ANTIMICROBIAL PHOSPHOLIPID COMPOSITIONS | CELESTIAL THERAPEUTICS, INC (US) | 2023-03-02 | — | — | WO | disclosed |
| US-20220273681-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS | NATIONAL JEWISH HEALTH | 2022-09-01 | — | — | US | disclosed |
| US-11278556-B2 | Methods and compositions for treating and preventing respiratory related diseases and conditions with xylitol-headgroup lipid analogs | NATIONAL JEWISH HEALTH (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130930-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS | PCTP, SGMS1, PHOSPHO1 | LMNA 683/4885L3MBTL1 3403/4885PTPN1 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.